<DOC>
	<DOCNO>NCT01825980</DOCNO>
	<brief_summary>To evaluate antiviral activity 3 day BZF961 . To determine safety tolerability BZF961 HCV patient . To evaluate pharmacokinetics BZF961 HCV patient .</brief_summary>
	<brief_title>Proof Concept Study Determine Safety Antiviral Effect BZF961 With Without Ritonavir Boosting Hepatitis C Virus Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Written informed consent must obtain assessment perform Male &amp; female treatment naive subject , age 1860 year age Hepatitis C genotype1 . Subjects must weight least 50kg participate study , must body mass index ( BMI ) within range 1836 kg/m2 Able communicate well investigator , understand comply study requirement . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever long : longer require local regulation , limitation participation investigational trial base local regulation . Subjects previously treat HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>